Strong CYP2C19 Inhibitors |
Clinical Impact | Coadministration of CIBINQO with strong CYP2C19 inhibitors increases the combined exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO [see Clinical Pharmacology (12.3)]. |
Intervention | Dosage reduction of CIBINQO is recommended when coadministered with strong CYP2C19 inhibitors [see Dosage and Administration (2.5)]. |
Moderate to Strong Inhibitors of both CYP2C19 and CYP2C9 |
Clinical Impact | Coadministration of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9 increases the exposure of abrocitinib and its two active metabolites, M1 and M2 which may increase the adverse reactions of CIBINQO [Clinical Pharmacology (12.3)]. |
Intervention | Avoid concomitant use of CIBINQO with drugs that are moderate to strong inhibitors of both CYP2C19 and CYP2C9. |
Strong CYP2C19 or CYP2C9 Inducers |
Clinical Impact | Coadministration of CIBINQO with strong CYP2C19 or CYP2C9 inducers decreases the combined exposure of abrocitinib and its two active metabolites, M1 and M2, which may result in loss of or reduced clinical response [see Clinical Pharmacology (12.3)]. |
Intervention | Avoid concomitant use of CIBINQO with strong CYP2C19 or CYP2C9 inducers. |